Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Rossano Cesari"'
Autor:
Anthony B. El-Khoueiry, Wendy J. Levin, Rachel Courtney, Rossano Cesari, Karen R. McLachlan, Xianxian Zheng, Sherry Li, M. Naveed Shaik, Wells A. Messersmith, Andrew J. Wagner
Purpose: To estimate the maximum tolerated dose (MTD) of single-agent PF-04449913, and to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity in patients with advanced tumors.Experimental Design: A 3+
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c07778c7f3dbbcfbeb4540ba209157b
https://doi.org/10.1158/1078-0432.c.6524900
https://doi.org/10.1158/1078-0432.c.6524900
Autor:
Ajay K. Gopal, Aron D. Thall, Bo Huang, Craig B. Davis, Ying Chen, Rossano Cesari, Michael J. Pishvaian, Shailender Bhatia, Ronald Levy, Toshihiko Doi, Aiwu R. He, Neil H. Segal
Supplemental legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d41a796eb3e053095d935505926b1b1b
https://doi.org/10.1158/1078-0432.22465487
https://doi.org/10.1158/1078-0432.22465487
Autor:
Ajay K. Gopal, Aron D. Thall, Bo Huang, Craig B. Davis, Ying Chen, Rossano Cesari, Michael J. Pishvaian, Shailender Bhatia, Ronald Levy, Toshihiko Doi, Aiwu R. He, Neil H. Segal
Purpose: Utomilumab (PF-05082566) is an agonistic mAb that engages the immune costimulatory molecule 4-1BB/CD137. In this first-in-human, phase I, open-label, multicenter, multiple-dose study (NCT01307267) we evaluated safety, tolerability, pharmacok
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::694989971a65a86e3429b40415deb7d4
https://doi.org/10.1158/1078-0432.c.6526034.v1
https://doi.org/10.1158/1078-0432.c.6526034.v1
Autor:
Patricia M. LoRusso, Kenneth A. Kern, Karen R. McLachlan, Patricia A. English, Jennifer M. Reynolds, Xianxian Zheng, Rossano Cesari, M. Naveed Shaik, Bo Huang, Arvind Dasari, Antonio Jimeno, James M. Cleary, Geoffrey I. Shapiro, Wells A. Messersmith
Purpose: To estimate the maximum tolerated dose (MTD) for continuous oral administration of the γ-secretase inhibitor PF-03084014, determine the recommended phase II dose (RP2D), and evaluate safety and preliminary activity in patients with advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15bd94532ba2fa13f8f6f263e26aff1b
https://doi.org/10.1158/1078-0432.c.6523016.v1
https://doi.org/10.1158/1078-0432.c.6523016.v1
Autor:
Anthony B. El-Khoueiry, Wendy J. Levin, Rachel Courtney, Rossano Cesari, Karen R. McLachlan, Xianxian Zheng, Sherry Li, M. Naveed Shaik, Wells A. Messersmith, Andrew J. Wagner
Supplementary Table 1. Table summarizing Treatment-emergent all-cause AEs experienced by {greater than or equal to}5% of patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45e7e02dd7e99fb4adee69aeca5c5f4a
https://doi.org/10.1158/1078-0432.22461758.v1
https://doi.org/10.1158/1078-0432.22461758.v1
Autor:
Patricia M. LoRusso, Kenneth A. Kern, Karen R. McLachlan, Patricia A. English, Jennifer M. Reynolds, Xianxian Zheng, Rossano Cesari, M. Naveed Shaik, Bo Huang, Arvind Dasari, Antonio Jimeno, James M. Cleary, Geoffrey I. Shapiro, Wells A. Messersmith
Supplemental Table S1. Tumor responses to single-agent treatment with PF-03084014 in patients with advanced solid malignancies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ee99a04b949092c73b488cf2938c43c
https://doi.org/10.1158/1078-0432.22455392.v1
https://doi.org/10.1158/1078-0432.22455392.v1
Autor:
Patricia M. LoRusso, Kenneth A. Kern, Karen R. McLachlan, Patricia A. English, Jennifer M. Reynolds, Xianxian Zheng, Rossano Cesari, M. Naveed Shaik, Bo Huang, Arvind Dasari, Antonio Jimeno, James M. Cleary, Geoffrey I. Shapiro, Wells A. Messersmith
Supplemental Figure S1 and Figure S2. Figure S1: Pharmacokinetic profiles of PF-03084014 following administration to patients with solid malignancies. Figure S2. Downregulation of Hes4 gene expression following treatment with PF-03084014 in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10eaa9a92aa1220bf80019b2b7576449
https://doi.org/10.1158/1078-0432.22455395.v1
https://doi.org/10.1158/1078-0432.22455395.v1
Autor:
Ajay K. Gopal, Aron D. Thall, Bo Huang, Craig B. Davis, Ying Chen, Rossano Cesari, Michael J. Pishvaian, Shailender Bhatia, Ronald Levy, Toshihiko Doi, Aiwu R. He, Neil H. Segal
Supplementary Table S1. Reason for treatment discontinuation Supplementary Table S2. Select laboratory abnormalities by maximum CTCAE grade Supplementary Table S3. Pharmacokinetic parameters for single-agent utomilumab (cycle 1) Supplementary Figure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d08d9dbb5c451b56c61fbcb212dfdf52
https://doi.org/10.1158/1078-0432.22465484
https://doi.org/10.1158/1078-0432.22465484
Autor:
George A. Calin, Carlo M. Croce, Larry R. Kaiser, Noel N. Williams, Massimo Negrini, Chang-gong Liu, Florencia Bullrich, Kristoffel R. Dumon, Tamotsu Kuroki, Shashi Rattan, Masayoshi Shimizu, Cinzia Sevignani, Rossano Cesari, Manuela Ferracin, Francesco Trapasso, Sai Yendamuri
Supplementary Table 3B from Tumor Suppressor Functions of ARLTS1 in Lung Cancers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab3f95618a5ba5674282d49876088edf
https://doi.org/10.1158/0008-5472.22367886
https://doi.org/10.1158/0008-5472.22367886
Autor:
George A. Calin, Carlo M. Croce, Larry R. Kaiser, Noel N. Williams, Massimo Negrini, Chang-gong Liu, Florencia Bullrich, Kristoffel R. Dumon, Tamotsu Kuroki, Shashi Rattan, Masayoshi Shimizu, Cinzia Sevignani, Rossano Cesari, Manuela Ferracin, Francesco Trapasso, Sai Yendamuri
Supplementary Methods, Tables 1-4, Figure Legend 1 from Tumor Suppressor Functions of ARLTS1 in Lung Cancers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::136a346f57cb391b07ddc40795a44e6b
https://doi.org/10.1158/0008-5472.22367892
https://doi.org/10.1158/0008-5472.22367892